AU2001283152A1 - Identification of cdnas associated with benign prostatic hyperplasia - Google Patents

Identification of cdnas associated with benign prostatic hyperplasia

Info

Publication number
AU2001283152A1
AU2001283152A1 AU2001283152A AU8315201A AU2001283152A1 AU 2001283152 A1 AU2001283152 A1 AU 2001283152A1 AU 2001283152 A AU2001283152 A AU 2001283152A AU 8315201 A AU8315201 A AU 8315201A AU 2001283152 A1 AU2001283152 A1 AU 2001283152A1
Authority
AU
Australia
Prior art keywords
identification
benign prostatic
prostatic hyperplasia
cdnas associated
cdnas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001283152A
Inventor
Robert R. Getzenberg
Prakash Kulkarni
William E. Munger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ore Pharmaceuticals Inc
Original Assignee
Ore Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ore Pharmaceuticals Inc filed Critical Ore Pharmaceuticals Inc
Publication of AU2001283152A1 publication Critical patent/AU2001283152A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2001283152A 2000-08-07 2001-08-07 Identification of cdnas associated with benign prostatic hyperplasia Abandoned AU2001283152A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22351100P 2000-08-07 2000-08-07
US60223511 2000-08-07
PCT/US2001/024710 WO2002012262A1 (en) 2000-08-07 2001-08-07 IDENTIFICATION OF cDNAs ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA

Publications (1)

Publication Number Publication Date
AU2001283152A1 true AU2001283152A1 (en) 2002-02-18

Family

ID=22836818

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001283152A Abandoned AU2001283152A1 (en) 2000-08-07 2001-08-07 Identification of cdnas associated with benign prostatic hyperplasia

Country Status (2)

Country Link
AU (1) AU2001283152A1 (en)
WO (1) WO2002012262A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078631A1 (en) * 2002-03-15 2003-09-25 Kaneka Corporation Novel genes

Also Published As

Publication number Publication date
WO2002012262A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
AU2001236731A1 (en) Transurethral volume reduction of the prostate (tuvor)
AU2001291859A1 (en) Use of copolycarbonates
AU2001234473A1 (en) Stabilized silica and methods of making and using the same
SI0968208T1 (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001288360A1 (en) Genomics-assisted rapid identification of targets
AU2002211370A1 (en) Inhibition of tgf-beta and uses thereof
AU2001284739A1 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
AU2001268442A1 (en) Identification of cdnas associated with benign prostatic hyperplasia
ZA991315B (en) Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia.
AU2000279176A1 (en) Locking nail and target appliance
AU2001283152A1 (en) Identification of cdnas associated with benign prostatic hyperplasia
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2876000A (en) Tyrosine kinase inhibitors and methods of using the same
AU2002232403A1 (en) Del-1 and benign prostatic hyperplasia
AU2002336520A1 (en) Method of treating benign prostatic hyperplasia and other beingn porstate conditions
AU2002210683A1 (en) Identification of hla-dr restricted hcv epitopes
AU2002317553A1 (en) Genes associated with benign prostatic hyperplasia
AU2001278204A1 (en) Methods of selecting and cloning animals
AU2002250315A1 (en) Gene (t23490) associated with benign prostatic hyperplasia
ZA991319B (en) Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
AU2002239466A1 (en) Gene associated with benign prostatic hyperplasia in humans
GB2418985B (en) Protein markers for human benign prostatic hyperplasia(BPH)